Is the FDA Too Tough on Medical Device Makers?
Ask about Knowledge at Wharton
Episode Description
Are the FDA's medical device regulations too hard, too soft, or just right? Wharton research indicates that the agency is on the right track. More: http://knlg.net/1Cb8KUR 📂 Health Care Management;Public Policy 🏷️ Research
Read the full transcriptHide the full transcript
- what we're doing in this paper is examining the approach that the FDA takes to medical device regulation and
- asking the question is it optimal or how close to optimal is it there's a raging
- debate about whether the FDA is too difficult on medical device regulation whether it's too hard for device
- manufacturers to get their device through the regulatory process or whether they're two lakhs and let too
- many potentially harmful devices through the process and so our research asked the question how much information does
- the FDA regulatory process generate for the market to use in deciding what to device to use in a given patient and
- should they require more information or less information and that's what our paper seeks to address
- what we did is we compared the behavior of devices in the US which has a much more difficult and rigorous regulatory
- standard to the European Union which has a much less informational requirements to get their devices through the
- approval process so we compared how the devices that were common in both markets
- how their market share evolved over time and we compare that to devices that were
- only offered in the EU which is what typically happens since the you market is much easier to answer there's many
- more devices and we examined how those market shares evolved over time and use that information to make inferences
- about the information that was being generated by the regulatory process and and then translate that into real
- consumer welfare measures what we found is that the US FDA regulatory process for the devices we
- looked at which were second generation stents cardiac stents was pretty close to optimal and while the EU which has
- very lacks regulatory standards was 22 lacks in that if they were to implement more rigorous informational requirements
- for getting devices through to the market they would improve consumer welfare and that surprises us that
- surprised us that the u.s. was so close to optimal given the calls for reforms at the FDA we kind of expected the FDA
- to be mean to too difficult to get through the trade off the regulator the regulator has to make is to if you
- require more information you delay the introduction of the device and make it more difficult for devices to enter the
- market raise the entry cost so the trade-off is that the regulator is making is the increased informational
- content of increasingly clinical trials for example in the benefits of that information so that's the kind of the
- benefit side the cost is that you delay entry and you and that's a real cost you
- have less access to device so there's a real access versus information trade-off
- here so one of the things we looked at is how could we improve the process and what we
- found is if we could make the post market informational generation process more informative that would generate a
- lot of welfare because then we could even relax the pre market requirements more and then more devices would get to
- market quicker and so that's the one thing that I think the takeaway is that there's a lot to be gained from
- increasing post market surveillance of medical devices hopefully this research will dispel the
- notion that the FDA is really way too difficult for particularly second generation devices I think our research
- pretty in my view pretty convincingly shows that they actually may be close to doing the right thing
- well there really is no other kind of similar analysis out there that's been able to credibly identify the causal
- relationship between regulatory regimes and this information content and the benefits that patients get from these
- devices so I we think our research is kind of one of a kind and there's some older research thats related to but we
- think ours is pretty unique and in that sense so what's next is you know it's we want
- to see kind of what market forces are at play that would allow medical device and
- cause medical device manufacturers to run their own clinical trials and provide this information on their own
- and not through you know requirements of the FDA and kind of providing information to the market and so that's
- kind of where we're next going with this research you
Brief Summary
The episode discusses FDA medical device regulation, comparing it to EU standards and suggesting improvements in post-market surveillance for better consumer welfare.
Key points
- FDA's Regulatory Process. Examining the FDA's approach to medical device regulation and its effectiveness.
- US vs EU Device Regulation. Comparing the rigorous US standards to the EU's less stringent requirements.
- Improving Post-Market Surveillance. Research suggests enhancing post-market processes could benefit consumer welfare.
Episode highlights
- US vs EU Device RegulationComparing the rigorous US standards to the EU's less stringent requirements.“The US FDA regulatory process was pretty close to optimal.”1:51Jun 25, 2015
- Improving Post-Market SurveillanceResearch suggests enhancing post-market processes could benefit consumer welfare.“There's a lot to be gained from increasing post market surveillance.”3:30Jun 25, 2015




